(Q41388317)

30 September 2017

1 reference

title

Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis (English)

1 reference

30 September 2017

Jeal W

1

1 reference

30 September 2017

Barradell LB

series ordinal

2

1 reference

30 September 2017

McTavish D

series ordinal

3

1 reference

30 September 2017

1 March 1997

1 reference

30 September 2017

1 reference

30 September 2017

53

1 reference

30 September 2017

415-434

1 reference

30 September 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199753030-00006

30 September 2017

0 references

cites work

Determination of 4-amino-1-hydroxybutane-1,1-bisphosphonic acid in urine by automated pre-column derivatization with 2,3-naphthalene dicarboxyaldehyde and high-performance liquid chromatography with fluorescence detection

1 reference

12 December 2020

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

12 December 2020

Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate

1 reference

12 December 2020

Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis

1 reference

12 December 2020

Esophagitis associated with the use of alendronate

1 reference

12 December 2020

Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment

1 reference

12 December 2020

Estrogens and Endometrial Cancer in a Retirement Community

1 reference

12 December 2020

Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage.

1 reference

12 December 2020

Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging

1 reference

12 December 2020

Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats

1 reference

12 December 2020

The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy

1 reference

12 December 2020

Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis

1 reference

12 December 2020

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

1 reference

12 December 2020

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

12 December 2020

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis

1 reference

12 December 2020

Rationale for the use of alendronate in osteoporosis

1 reference

12 December 2020

Renal handling of alendronate in rats. An uncharacterized renal transport system

1 reference

12 December 2020

Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia

1 reference

12 December 2020

Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy

1 reference

12 December 2020

Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin

1 reference

12 December 2020

Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats.

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats

1 reference

12 December 2020

Preclinical pharmacology of alendronate

1 reference

12 December 2020

Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis

1 reference

12 December 2020

Determination of bisphosphonate drugs in pharmaceutical dosage formulations by ion chromatography with indirect UV detection

1 reference

12 December 2020

New bisphosphonates in osteoporosis

1 reference

12 December 2020

What constitutes evidence for drug efficacy in osteoporosis?

1 reference

12 December 2020

Studies of the oral bioavailability of alendronate.

1 reference

12 December 2020

Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties

1 reference

12 December 2020

Evidence of estrogen receptors in normal human osteoblast-like cells

1 reference

12 December 2020

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

1 reference

12 December 2020

Long-term fracture prediction by bone mineral assessed at different skeletal sites

1 reference

12 December 2020

Relationship between trabecular vertebral body density and fractures: a quantitative definition of spinal osteoporosis.

1 reference

12 December 2020

Clinical pharmacology of alendronate sodium

1 reference

12 December 2020

Effects of five daily 1 h infusions of alendronate in Paget's disease of bone

1 reference

12 December 2020

Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone

1 reference

12 December 2020

Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

1 reference

12 December 2020

Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease

1 reference

12 December 2020

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

12 December 2020

Ability of four different techniques of measuring bone mass to diagnose vertebral fractures in postmenopausal women.

1 reference

12 December 2020

A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Reduced mortality associated with long-term postmenopausal estrogen therapy.

1 reference

12 December 2020

The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women

1 reference

12 December 2020

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers

1 reference

12 December 2020

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis

1 reference

12 December 2020

Aminohydroxybutane bisphosphonate and clenbuterol prevent bone changes and retard muscle atrophy respectively in tail-suspended rats

1 reference

12 December 2020

Effects of aminohydroxybutane bisphosphonate on bone growth when administered after hind-limb bone loss in tail-suspended rats

1 reference

12 December 2020

Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake.

1 reference

12 December 2020

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

1 reference

12 December 2020

The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons

1 reference

12 December 2020

Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals

1 reference

12 December 2020

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

1 reference

12 December 2020

10.2165/00003495-199753030-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

30 September 2017

0 references

1 reference